CA
VRNA

CoreCap Advisors’s Verona Pharma VRNA Stock Holding History

CoreCap Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-285
Closed -$27K – 2947
2025
Q2 		$27K Hold
285
– – ﹤0.01% 1499
2025
Q1 		$18.1K Hold
285
– – ﹤0.01% 1579
2024
Q4 		$13.2K Sell
285
-194
-41% -$7.28K ﹤0.01% 1673
2024
Q3 		$13.8K Buy
+479
New +$11.8K ﹤0.01% 1688
2024
Q2 		– Sell
-657
Closed -$10.6K – 2570
2024
Q1 		$10.6K Buy
+657
New +$11.4K ﹤0.01% 1727
2022
Q4 		$15.7K Buy
+600
New +$7.99K ﹤0.01% 1383
2022
Q3 		– Sell
-600
Closed -$3K – 2067
2022
Q2 		$3K Buy
+600
New +$2.57K ﹤0.01% 1815
2022
Q1 		– Sell
-600
Closed -$4K – 2066
2021
Q4 		$4K Buy
+600
New +$3.06K ﹤0.01% 1830

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CoreCap Advisors's VRNA Position: Q3 2025 in Review

CoreCap Advisors sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 285 shares — an estimated $27K sold.

CoreCap Advisors first reported a position in VRNA in Q4 2021 and held it in 8 quarters. The position peaked at $27K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • CoreCap Advisors reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • CoreCap Advisors sold 285 Verona Pharma shares in Q3 2025, an estimated $27K.
  • CoreCap Advisors first reported a position in Verona Pharma in Q4 2021 and held it in 8 quarters.
  • CoreCap Advisors's Verona Pharma position peaked at $27K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on CoreCap Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.